OHSU Center for Specialized Data Analysis as part of the GDAN
OHSU Center for Specialized Data Analysis as part of the GDAN
批准号:
10004583
负责人:
Emek Demir
金额:
$42.18万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-13 至 2021-08-31
关键词:
AddressAlgorithmsAreaBioinformaticsBiologicalCancer CenterChargeClinicalClinical TrialsClinical Trials DesignClonal EvolutionCodeCommunitiesCompetenceComputer AnalysisComputer SystemsComputer softwareComputing MethodologiesDataData AnalysesData SetDetectionDevelopmentDistributed SystemsDreamsEnsureEvolutionGenetic HeterogeneityGenetic TranscriptionGenomicsGenotypeGoalsHeterogeneityHuman ResourcesIndividualInfrastructureInterventionKnowledgeLearningMalignant NeoplasmsMalignant neoplasm of prostateManualsMethodsMutationNeoplasm MetastasisPathway AnalysisPathway interactionsPatientsPharmacologic SubstancePhenotypePrevention strategyPrognostic MarkerResearch PersonnelResistanceRunningSamplingServicesSiteSpecialized CenterStructureSurvival RateThe Cancer Genome AtlasTherapeuticTherapeutic InterventionTimeTrainingVariantWorkbioinformatics toolcancer clinical trialcancer genomicscancer initiationcancer preventioncluster computingcomputer infrastructurecomputerized toolsdata analysis pipelinediagnostic biomarkerexperiencegenetic evolutiongenomic dataimprovedinnovationmultidisciplinarynovelnovel diagnosticsnovel strategiespatient subsetsprecision medicineprogramsresponsesuccesstherapy resistanttranscriptome sequencingtreatment strategytumorwebinarworking group
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Recent advances in therapeutics have improved survival rates for many cancers. However, nearly all
metastatic tumors are incurable, and resistance to therapeutic interventions is nearly universal. There are
many reasons for our lack of progress-foremost of which is lack of understanding of mechanisms of response
and resistance and lack of markers to identify subsets of patients ideally-suited for specific treatments.
Our team brings enormous experience in TCGA and other multi-disciplinary coordinated projects, such as
BEAT-AML, and the Stand Up to Cancer West Coast Prostate Cancer Dream Team. The Cancer Genome
Atlas (TCGA) was successful because multi-disciplinary teams worked together to create new and innovative
knowledge about cancer and we intend to ensure that the GDAN is equally successful. In this application, we
have assembled a team of proven investigators from four of the different TCGA groups to extend the
successes of TCGA to the projects managed by the Center for Cancer Genomics. Our team will continue our
outstanding capabilities at analyzing and interpreting cancer genomic data by deploying data analysis pipelines
that support the key capabilities of the network.
In addition to the our experience in coordinated network studies, we bring experience with clinical trial design
and interpretation. Further, the team has deep expertise at building the computational infrastructure necessary
for the GDAN to succeed. For example, in the domain of distributed computing we have deploy pipelines for
execution at many sites. We also bring novel methods for integrative pathways and analysis. Finally, we bring
our experiences with competitive challenges that ensure that we can identify and deploy the most effective
methods for genomic data analyses.
Using these strengths we will support the GDAN and the Analysis Working Groups (AWGs) that it serves with
two principal objectives. The first objective and second objective, per the RFA, are the “Development of
innovative bioinformatics and computational tools and methodologies”, which will allow us to make clinical and
biological correlations and to “Conduct Integrative analysis of data sets generated by GCCs using the
bioinformatics tools developed by each GDAC.” We will achieve these objectives in five specific aims, one
administrative aim to support the GDAN and four aims, one for each of the areas where we propose a
competency.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.
DOI:
10.1016/j.celrep.2018.03.077
发表时间:
2018-04-03
期刊:
Cell reports
影响因子:
8.8
作者:
[Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN, Cancer Genome Atlas Research Network, Bathe OF, Liang H]
通讯作者:
Liang H
DOI:
10.1016/j.celrep.2018.03.047
发表时间:
2018-04-03
期刊:
Cell reports
影响因子:
8.8
作者:
[Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H, Cancer Genome Atlas Research Network, Piwnica-Worms H, Ma L, Liang H]
通讯作者:
Liang H
DOI:
10.1016/j.celrep.2018.01.088
发表时间:
2018-04-03
期刊:
Cell reports
影响因子:
8.8
作者:
[Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG, Cancer Genome Atlas Research Network, Buonamici S, Yu L]
通讯作者:
Yu L
DOI:
10.1016/j.ccell.2018.03.007
发表时间:
2018-04-09
期刊:
Cancer cell
影响因子:
50.3
作者:
[Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Cancer Genome Atlas Research Network, Cherniack AD, Beroukhim R, Meyerson M]
通讯作者:
Meyerson M
DOI:
10.1016/j.celrep.2018.03.086
发表时间:
2018-04-03
期刊:
Cell reports
影响因子:
8.8
作者:
[Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J, Cancer Genome Atlas Research Network, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V]
通讯作者:
Thorsson V
共 7 条
Omic and Multidimensional Spatial Atlas of Metastatic Breast Cancer
-
批准号:10818062
-
项目类别:
-
资助金额:$92.33万
-
财政年份:2023
-
负责人:Emek Demir
-
依托单位:
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers
-
批准号:10471932
-
项目类别:
-
资助金额:$174.71万
-
财政年份:2018
-
负责人:Emek Demir
-
依托单位:
Measuring, Modeling and Controlling Heterogeneity
-
批准号:10166783
-
项目类别:
-
资助金额:$185.13万
-
财政年份:2017
-
负责人:Emek Demir
-
依托单位:
海外基金